Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis – a potential biomarker role for LysoPC

por Rindlisbacher, Barbara, Schmid, Cornelia, Geiser, Thomas, Bovet, Cédric, Funke-Chambour, Manuela
Publicado 2018

Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification

por Zoni, Eugenio, Minoli, Martina, Bovet, Cédric, Wehrhan, Anne, Piscuoglio, Salvatore, Ng, Charlotte K. Y., Gray, Peter C., Spahn, Martin, Thalmann, George N., Kruithof-de Julio, Marianna
Publicado 2019

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation

por Willekens, Guido, Studt, Jan‐Dirk, Mendez, Adriana, Alberio, Lorenzo, Fontana, Pierre, Wuillemin, Walter A., Schmidt, Adrian, Graf, Lukas, Gerber, Bernhard, Bovet, Cedric, Sauter, Thomas C., Nagler, Michael
Publicado 2021

Prothrombinase-Induced Clotting Time to Measure Drug Concentrations of Rivaroxaban, Apixaban, and Edoxaban in Clinical Practice: A Cross-Sectional Study

por Sathanantham, Vepusha, Alberio, Lorenzo, Bovet, Cédric, Fontana, Pierre, Gerber, Bernhard, Graf, Lukas, Mendez, Adriana, Sauter, Thomas C., Schmidt, Adrian, Studt, Jan-Dirk, Wuillemin, Walter A., Nagler, Michael
Publicado 2022

Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A

por Erzinger, Melanie M., Bovet, Cédric, Hecht, Katrin M., Senger, Sabine, Winiker, Pascale, Sobotzki, Nadine, Cristea, Simona, Beerenwinkel, Niko, Shay, Jerry W., Marra, Giancarlo, Wollscheid, Bernd, Sturla, Shana J.
Publicado 2016

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator

por Burger, Annika, Studt, Jan-Dirk, Mendez, Adriana, Alberio, Lorenzo, Fontana, Pierre, Wuillemin, Walter A., Schmidt, Adrian, Graf, Lukas, Gerber, Bernhard, Bovet, Cédric, Sauter, Thomas C., Binder, Nikolaus B., Nagler, Michael
Publicado 2023

Delivery of Rapamycin Using In Situ Forming Implants Promotes Immunoregulation and Vascularized Composite Allograft Survival

por Sutter, Damian, Dzhonova, Dzhuliya V., Prost, Jean-Christophe, Bovet, Cedric, Banz, Yara, Rahnfeld, Lisa, Leroux, Jean-Christophe, Rieben, Robert, Vögelin, Esther, Plock, Jan A., Luciani, Paola, Taddeo, Adriano, Schnider, Jonas T.
Publicado 2019

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements

por Meihandoest, Tamana, Studt, Jan-Dirk, Mendez, Adriana, Alberio, Lorenzo, Fontana, Pierre, Wuillemin, Walter A., Schmidt, Adrian, Graf, Lukas, Gerber, Bernhard, Maeder, Gabriela Monika, Bovet, Cédric, Sauter, Thomas C., Nagler, Michael
Publicado 2021

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study

por Meihandoest, Tamana, Studt, Jan-Dirk, Mendez, Adriana, Alberio, Lorenzo, Fontana, Pierre, Wuillemin, Walter A., Schmidt, Adrian, Graf, Lukas, Gerber, Bernhard, Amstutz, Ursula, Bovet, Cedric, Sauter, Thomas C., Asmis, Lars M., Nagler, Michael
Publicado 2022